DoD Tuberous Sclerosis Complex Idea Development Award

archived

The TSCRP Idea Development Award (IDA) mechanism was first offered in FY02. Since that time, 135 IDA applications have been received, and 29 have been recommended for funding. The IDA supports high-impact, innovative research that will drive the field forward. Important aspects of the IDA are as follows: 1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of TSC research. The proposed research is expected to make an important and original contribution to advancing TSC research or patient care. 2. Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives or exhibit other uniquely creative qualities. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. 3. Preliminary Data: Preliminary data originating from the PI, research team, or collaborator that is relevant to the proposed project is required. Research involving participation of human subject use is permitted; however, clinical trials are NOT ALLOWED under this funding opportunity. In general, a clinical trial is defined as a prospective study in which an intervention (e.g., device, drug, behavioral or surgical procedure, or other) is tested on human subjects for a measurable outcome. Principal Investigators (PIs) wishing to apply for funding for a clinical trial should utilize the Clinical Research Award mechanism. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical

High